NASDAQ:TROV

Cardiff Oncology Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$5.32
-0.01 (-0.19 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.25
$5.53
50-Day Range
$1.19
$24.71
52-Week Range
$0.70
$3.46
Volume371,877 shs
Average Volume648,892 shs
Market Capitalization$58.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.


Cardiff Oncology logo

About Cardiff Oncology

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.99 out of 5 stars

Medical Sector

1570th out of 2,220 stocks

Biological Products, Except Diagnostic Industry

187th out of 213 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Cardiff Oncology (NASDAQ:TROV) Frequently Asked Questions

What stocks does MarketBeat like better than Cardiff Oncology?

Wall Street analysts have given Cardiff Oncology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardiff Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:TROV) posted its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%.
View Cardiff Oncology's earnings history
.

When did Cardiff Oncology's stock split? How did Cardiff Oncology's stock split work?

Cardiff Oncology's stock reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of Cardiff Oncology stock prior to the reverse split would have 17 shares after the split.

Who are Cardiff Oncology's key executives?

Cardiff Oncology's management team includes the following people:
  • Mark Erlander, Chief Executive Officer & Director
  • Vicki Kelemen, Chief Operating Officer & Executive Vice President
  • Brigitte Lindsay, Secretary & Vice President-Finance

Who are some of Cardiff Oncology's key competitors?

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Idera Pharmaceuticals (IDRA).

What is Cardiff Oncology's stock symbol?

Cardiff Oncology trades on the NASDAQ under the ticker symbol "TROV."

What is Cardiff Oncology's stock price today?

One share of TROV stock can currently be purchased for approximately $5.32.

How much money does Cardiff Oncology make?

Cardiff Oncology has a market capitalization of $58.58 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

What is Cardiff Oncology's official website?

The official website for Cardiff Oncology is www.trovagene.com.

Where are Cardiff Oncology's headquarters?

Cardiff Oncology is headquartered at 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121.

How can I contact Cardiff Oncology?

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at (858) 952-7570 or via email at [email protected]


This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.